BioMarin's $4.8 Billion Amicus Acquisition: Immediate Revenue Acceleration and Rare Disease Expansion Ahead
Acquisition Broadens BioMarin’s Rare Disease Reach with Two Fast-Growing Therapies
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) made headlines this morning after announcing a $4.8 billion all-cash acquisition of Amicus Therapeutics (NASDAQ: FOLD). This move is set to bring two marketed, high-growth rare disease drugs—Galafold® for Fabry disease and Pombiliti® + Opfolda® for Pompe disease—directly under BioMarin’s global commercial umbrella.
The acquisition isn’t just a headline grabber. The newly combined portfolio posted $599 million in net product revenue over the past four quarters, positioning BioMarin for immediate financial gains and deeper market penetration in the rare disease space. The deal is expected to be immediately accretive to non-GAAP diluted EPS, with substantial additional benefits starting in 2027.
Key Deal Details: All-Cash, Accretive, and Premium Valuation
BioMarin will pay $14.50 per Amicus share—a premium of 33% to FOLD's last close, 46% above the 30-day volume-weighted average, and 58% above the 60-day volume-weighted average. The acquisition will be financed with cash on hand and roughly $3.7 billion in new non-convertible debt, with BioMarin targeting gross leverage below 2.5x within two years of close. The transaction has been unanimously approved by both boards and is set to close in the second quarter of 2026, pending customary conditions and regulatory approval.
| Acquisition Value | Amicus Per Share Price | Revenue Added (Last 4Q) | Financing Structure | Deal Premium (to Last Close) | Expected EPS Impact |
|---|---|---|---|---|---|
| $4.8 Billion | $14.50 | $599 Million | Cash + $3.7B Debt | 33% | Accretive within 12 months; substantial in 2027 |
Pipeline and Portfolio Expansion: Galafold and Pombiliti + Opfolda in Focus
This acquisition strategically diversifies BioMarin’s commercial portfolio, adding Galafold—approved in 40+ countries and protected in the U.S. until 2037—and Pombiliti + Opfolda, a newly launched therapy for Pompe disease. These therapies expand BioMarin’s reach in enzyme therapies and open new doors in global rare disease treatment, with ongoing opportunities to bring these solutions to more markets and patients worldwide.
The deal also includes Amicus’s U.S. rights to DMX-200, an investigational therapy for focal segmental glomerulosclerosis (FSGS), offering potential long-term upside beyond the current portfolio.
Immediate Financial Upside: Revenue and EPS Acceleration Expected
BioMarin expects to accelerate its revenue growth right after the transaction closes, boosting its compound annual growth rate (CAGR) through 2030 and beyond. The transaction’s accretive impact on non-GAAP diluted EPS should begin within 12 months of closing and grow further as product synergies ramp up. With combined strong cash flow generation and a disciplined approach to debt management, the company projects a rapid return to lower leverage levels, adding another layer of confidence for stakeholders.
Strategic Takeaways: BioMarin Signals Confidence, Scale, and Rare Disease Commitment
This move signals a confident strategic step for BioMarin: diversifying risk, growing immediately, and building a stronger presence in rare disease biotech. With high-growth assets and resolved U.S. patent litigation on Galafold (securing market exclusivity through January 2037), the deal positions BioMarin as a major player ready to leverage global reach and manufacturing scale. The premium valuation for Amicus also reflects confidence in synergies and market expansion opportunities.
For investors, the acquisition not only brings financial acceleration but may offer broader exposure to the next generation of rare disease treatments and innovation. The market reaction has been swift, with BMRN stock at $60.88 as of 10:31 AM—a clear reflection of investor enthusiasm for the company’s new direction.
What to Watch Next: Closing Timeline, Revenue Growth, and Regulatory Progress
As BioMarin works through the closing process—expected in the second quarter of 2026—stakeholders will want to watch for updates on regulatory clearances, integration plans, and product expansion strategies, particularly in emerging markets. Additionally, keep an eye on revenue progression and EPS growth targets as early signs of post-acquisition success.
Bottom line: BioMarin’s $4.8 billion Amicus acquisition is about more than just portfolio growth—it’s a strong signal of intent, positioning the company to accelerate growth and set the pace in rare disease therapy innovation.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI